Suchergebnisse - (Person:"Bafadhel, Mona")

PubPharm (9)

1

Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial

enthalten in: Annals of internal medicine | 2023

von Reis, G. | Dos Santos Moreira Silva, E. | Medeiros Silva, D. | +133

2

Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids : a mechanistic analysis

enthalten in: The Lancet. Respiratory medicine | 2022

von Baker, J. | Mahdi, M. | Nicolau, D. | +7

CommentIn: Lancet Respir Med. 2022 Jun;10(6):526-527. - PMID 35397799

3

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges : A Post-Hoc Analysis of Data from ETHOS

enthalten in: International journal of chronic obstructive pulmonary disease | 2022

von Bafadhel, M. | Rabe, K. | Martinez, F. | +6

4

High-dose budesonide for early COVID-19 - Authors' reply

enthalten in: Lancet (London, England) | 2021

von Hobbs, F. | Yu, L. | Saville, B. | +2

CommentOn: Lancet. 2021 Sep 4;398(10303):843-855. - PMID 34388395

5

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE) : a randomised, controlled, open-label, adaptive platform trial

enthalten in: Lancet (London, England) | 2021

von Yu, L. | Bafadhel, M. | Dorward, J. | +50

CommentIn: Lancet. 2021 Sep 4;398(10303):818-819. - PMID 34388397

6

Inhaled budesonide in the treatment of early COVID-19 (STOIC) : a phase 2, open-label, randomised controlled trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Ramakrishnan, S. | Nicolau, D. | Langford, B. | +21

CommentIn: Lancet Respir Med. 2021 Apr 9;:. - PMID 33844998

7

Inhaled budesonide for early treatment of COVID-19 - Authors' reply

enthalten in: The Lancet. Respiratory medicine | 2021

von Ramakrishnan, S. | Bafadhel, M.

CommentOn: Lancet Respir Med. 2021 Jul;9(7):763-772. - PMID 33844996

8

Symptomatic COPD : is it time for triple therapy?

enthalten in: The Lancet. Respiratory medicine | 2018

von Bafadhel, M.

CommentOn: Lancet Respir Med. 2018 Oct;6(10):747-758. - PMID 30232048

9

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease : a post-hoc analysis of three randomised trials

enthalten in: The Lancet. Respiratory medicine | 2018

von Bafadhel, M. | Peterson, S. | De Blas, M. | +4

CommentIn: Lancet Respir Med. 2018 Feb;6(2):78-80. - PMID 29331310

1
[1]